

Application No. 09/533,029  
Att'y Docket No. MBI-0010

### AMENDMENT

#### In the Claims:

Cancel claims 61, 62, 63-68, 69, and 70-76 without prejudice.

Reiterated claims are as follows.

37. (Reiterated) A transgenic plant comprising a recombinant polynucleotide encoding SEQ ID NO: 18, and said transgenic plant has enhanced tolerance to fungal disease due to expression of SEQ ID NO: 18.

39. (Reiterated) The transgenic plant of claim 37, wherein the recombinant polynucleotide comprises SEQ ID NO: 17.

40. (Reiterated) The transgenic plant of claim 37, wherein the recombinant polynucleotide further comprises one or more regulatory sequences.

41. (Reiterated) The transgenic plant of claim 40, wherein said one or more regulatory sequences are selected from the group consisting of a promoter, a transcription initiation start site, an RNA processing signal, a transcription termination site, and a polyadenylation signal.

42. (Reiterated) The transgenic plant of claim 41, wherein said promoter is constitutive, inducible, or tissue-specific.

44. (Reiterated) The transgenic plant of claim 37, wherein said fungal disease is caused by *Fusarium*, *Erysiphe*, *Sclerotinia* or *Botrytis*.

45. (Reiterated) A method for enhancing the disease tolerance or resistance of a plant comprising transforming a plant with a recombinant polynucleotide encoding SEQ ID NO: 18, and said transgenic plant has enhanced tolerance to fungal disease due to expression of SEQ ID NO: 18.

47. (Reiterated) The method of claim 45, wherein the recombinant polynucleotide comprises SEQ ID NO: 17.

Application No. 09/533,029  
Atty Docket No. MBI-0010

48. (Reiterated) The method of claim 45, wherein the recombinant polynucleotide further comprises one or more regulatory sequences.

49. (Reiterated) The method of claim 48, wherein said one or more regulatory sequences are selected from the group consisting of a promoter, a transcription initiation start site, an RNA processing signal, a transcription termination site, and a polyadenylation signal.

50. (Reiterated) The method of claim 49, wherein said promoter is constitutive, inducible, or tissue-specific.

52. (Reiterated) The transgenic plant of claim 45, wherein said fungal disease is caused by *Fusarium*, *Erysiphe*, *Sclerotinia* or *Botrytis*.

53. (Reiterated) A method for altering the expression levels of at least one gene in a plant comprising transforming the plant with a recombinant polynucleotide encoding SEQ ID NO: 18, and said transgenic plant has enhanced tolerance to fungal disease due to expression of SEQ ID NO: 18.

55. (Reiterated) The method of claim 53, wherein the recombinant polynucleotide comprises SEQ ID NO: 17.

56. (Reiterated) The method of claim 53, wherein the recombinant polynucleotide further comprises one or more regulatory sequences.

57. (Reiterated) The method of claim 56, wherein said one or more regulatory sequences are selected from the group consisting of a promoter, a transcription initiation start site, an RNA processing signal, a transcription termination site, and a polyadenylation signal.

58. (Reiterated) The method of claim 57, wherein said promoter is constitutive, inducible, or tissue-specific.

60. (Reiterated) The transgenic plant of claim 53, wherein said fungal disease is caused by *Fusarium*, *Erysiphe*, *Sclerotinia* or *Botrytis*.